News | June 23, 2026
Teva closes $700M Emalex acquisition
Bolstering neuroscience push with late-stage Tourette therapy
Bolstering neuroscience push with late-stage Tourette therapy
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Report reveals growing confidence in AI-driven decision-making, but highlights persistent challenges in scaling digital investments and converting innovation into measurable business value
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Samelisant will be the centerpiece of Suven’s scientific presence
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
Company experts to participate in eight sessions covering AI-powered clinical development, regulatory innovation, oncology research, and patient engagement
Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
